DALLAS, Dec. 13 /PRNewswire/ -- Susan G. Komen for the Cure, the global
leader in the movement to end breast cancer forever, has announced the
recipients of the 2007 Komen Brinker Award for Scientific Distinction, the
organization's highest award of merit.

This year's recipients are Leslie Bernstein, Ph.D., professor,
department of preventive medicine and the inaugural holder of the AFLAC,
Inc. Chair in Cancer Research at the University of Southern California, Los
Angeles, and Joe W. Gray, Ph.D., director, division of life sciences,
Lawrence Berkeley National Laboratory, Berkeley, Calif.

Dr. Bernstein and Dr. Gray will be formally recognized during the 30th
annual San Antonio Breast Cancer Symposium (SABCS), a major international
gathering of breast cancer researchers, clinicians and patient advocacy
organizations, Dec. 13-16 in San Antonio. The two recipients will deliver
lectures for SABCS attendees at 3:45 p.m. Dec. 13 in Exhibit Hall D of the
Henry B. Gonzalez Convention Center. Both will receive cash awards of
$25,000 and a crystal award.

The Art and Science of Delivering the Cures

The evening of Dec. 13, Susan G. Komen for the Cure founder Ambassador
Nancy G. Brinker will be the featured speaker at a gala dinner held at the
Gonzalez Center in honor of the Komen Brinker award recipients. In
recognition of the art and the science involved in both research and
clinical endeavors, Komen has themed the evening 'Toward a Culture of
Discovery: Progress and Passion in the Search for the Cures.' Susan G.
Komen for the Cure's Art for the Cure program, which features a special
traveling exhibition of Ambassador Brinker's collection of Hungarian art,
will be featured at the dinner event to celebrate the organizations 25th
anniversary and the 15th anniversary of the Komen Brinker Award for
Scientific Distinction.

The Brinker Award for Scientific Distinction was established in 1992 to
honor the efforts of acknowledged pioneers in two critically important
components of the fight to end breast cancer: clinical work and basic
research. Since the award's establishment, the roster of Komen Brinker
Award for Scientific Distinction laureates has grown to include names of
researchers connected with some of the most significant advancements made
in the way breast cancer is diagnosed and treated as well as the way
research into the disease is conducted. This year, former Komen Brinker
award laureates will also be acknowledged for their achievements.

Bernstein: Pioneer in Linking Exercise, Breast Cancer Risk

Leslie Bernstein, Ph.D., pioneered research on the link between
physical activity and breast cancer, which is now well established. This
research provides an evidence base for one of the few recommendations that
can be made for breast cancer risk reduction. In addition to her studies on
physical activity, she has contributed to the study of body size, including
weight gain and obesity, another area of inquiry that has yielded insights
into breast cancer risk reduction for post-menopausal women.

As director of the Los Angeles Surveillance Epidemiology and End
Results (SEER) Registry, Dr. Bernstein is a leader in efforts to understand
patterns in breast cancer incidence, including the troubling rise in risk
among new immigrants to California. This work is fundamental to efforts in
addressing breast cancer disparities and in anticipating risk among
Asian-American women. Dr. Bernstein has a long and distinguished history of
leadership at the University of Southern California, where she has advanced
opportunities for women in science while serving as a model for the next
generation of research professionals.

Dr. Bernstein will receive the 2007 Komen Brinker Award for Scientific
Distinction in the category of clinical research.

Gray: Developing Technology to Solve Challenging Biomedical Problems

Joe W. Gray, Ph.D., is recognized as a pioneer in the development of
innovative technologies that enable researchers to pursue original avenues
of inquiry into challenging biomedical problems. The sum of his impact,
innovation and creativity over the course of his career are directly linked
to translational research which many leading scientists acknowledge will
lead to real improvements for people living with breast cancer.

He is credited with the development and implementation of many
important technologies, including high-speed sorting; flow karyotyping; the
first chromosome painting probes; development of interphase fluorescent in
situ hybridization (FISH); and the first demonstration using FISH showing
ERBB2 amplification and BCR-ABL translocation, both of which are critically
important to current patient management. His list of credits also includes
brdU/DNA analysis of cell cycle progression; comparative genomic
hybribidization (CGH); BAC End Sequencing (BES) and, more recently,
nanotechnology.

Dr. Gray was an early adopter of technologies such as transcriptional
profiling, high throughput analysis, SNP array CGH and molecular inversion
probes. By integrating data received from these technologies, Dr. Gray has
made significant advancements in developing methods that will lead to
improved patient outcomes. Specifically, his work is leading to
groundbreaking research in the determination of how to improve breast
cancer detection and treatment. His efforts are helping to increase the
translation of basic research to the clinic. Dr. Gray is a staunch
proponent of collaborative, or "team" science. He supports an active
academic-industrial collaborative enterprise to encourage industry to
invest in, develop and implement technologies needed to combat breast
cancer.

About Susan G. Komen for the Cure

Nancy G. Brinker promised her dying sister, Susan G. Komen, she would
do everything in her power to end breast cancer forever. In 1982, that
promise became Susan G. Komen for the Cure and launched the global breast
cancer movement. Today, Komen for the Cure is the world's largest
grassroots network of breast cancer survivors and activists fighting to
save lives, empower people, ensure quality care for all and energize
science to find the cures. Thanks to events like the Komen Race for the
Cure, we have invested nearly $1 billion to fulfill our promise, becoming
the largest source of nonprofit funds dedicated to the fight against breast
cancer in the world. For more information about Susan G. Komen for the
Cure, breast health or breast cancer, visit http://www.komen.org or call
1-877 GO KOMEN.

(Date:8/15/2017)... ... 15, 2017 , ... Nanomedical Diagnostics , a cutting-edge ... the launch of the new NHS Agile biosensor chip . The new ... a wide range of molecules, including small and large molecules, peptides, proteins, and ...

(Date:8/15/2017)... ... August 15, 2017 , ... Coffea arabica ... biotic and abiotic factors. During this educational webinar, participants will learn about the ... as gain a better understanding of how genomics is important for coffee breeding ...

(Date:8/10/2017)... Philadelphia, PA (PRWEB) , ... August 09, 2017 ... ... back to the classroom next week-- as students. From August 14th through the ... Institute. The institute, which debuted in the summer of 2016, provides Philadelphia-based middle ...

(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...

(Date:3/24/2017)... , Mar 24, 2017 Research and ... Access System Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 15.1% over the next ... This industry report analyzes the market estimates and forecasts for all ...